Tempest Therapeutics
TPST
20 hedge funds and large institutions have $31.7M invested in Tempest Therapeutics in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 6 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
54% more capital invested
Capital invested by funds: $20.5M → $31.7M (+$11.2M)
2.51% more ownership
Funds ownership: 0% → 2.51% (+2.5%)
13% less funds holding
Funds holding: 23 → 20 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
74% less call options, than puts
Call options by funds: $168K | Put options by funds: $634K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.46M |
| 2 |
BlackRock
New York
|
+$1.16M |
| 3 |
Millennium Management
New York
|
+$435K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$349K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$303K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$803K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$465K |
| 3 |
DMK
David M. Knott
|
-$155K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$117K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$96K |
TPST Hedge Fund Activity: Q3 2021 in Review
20 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2021, worth a combined $31.7M — up 54% from $20.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TPST and 3 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $4.46M. The largest seller was Monashee Investment Management, cutting an estimated $803K.
- 20 institutional investors held Tempest Therapeutics (TPST) as of Q3 2021, down from 23 in Q2 2021.
- Funds reported $31.7M of Tempest Therapeutics stock for Q3 2021, up 54% quarter-over-quarter.
- 3 funds opened new Tempest Therapeutics positions in Q3 2021 and 6 closed out, a net change of -3 holders.
- The largest Tempest Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $4.46M added.
- The largest Tempest Therapeutics seller in Q3 2021 was Monashee Investment Management, an estimated $803K sold.
Based on aggregated 13F filings for Q3 2021.